GE HealthCare is deepening its push into AI-driven breast cancer screening, announcing an expanded collaboration with DeepHealth, the AI health informatics subsidiary of RadNet. 

 

The move aims to accelerate the development, commercialization, and global rollout of advanced AI-powered mammography tools.

 

The partnership builds on an initial 2024 collaboration that paired DeepHealth’s AI screening workflow with GE HealthCare’s Senographe Pristina mammography system to improve image interpretation and streamline clinical operations. 

 

The next phase expands internationally, introducing second-reader AI workflows and broader access to DeepHealth’s breast cancer screening capabilities.

 

GE HealthCare is now positioning a cloud-based, modular “Breast Suite” designed to integrate directly into existing imaging systems. When combined with GE HealthCare’s Pristina Via platform, the companies say the system supports scalable, high-efficiency screening programs with faster, more consistent clinical decision-making.

 

“At GE HealthCare, we’re advancing women’s health through precision care built around the unique needs of women and enhanced by the power of AI,” said Jyoti Gupta, President and CEO, Women’s Health and X-ray at GE HealthCare. 

 

“By integrating Breast Suite AI with our Pristina Via mammography system, we’re helping clinicians detect breast cancer early with greater confidence. These innovations move us closer towards truly personalized prevention and care for women.”

 

Clinical data cited by the companies points to a 21% increase in breast cancer detection rates in large US real-world analyses when using DeepHealth’s multistage AI workflow compared to standard care. The system’s “Timely Alerts” feature can also flag suspicious cases within minutes, integrating directly into clinical workflows.

 

“Pristina Via and Breast Suite have transformed how we approach breast cancer detection,” said Meghna Krishnan, Owner, URPrecious Imaging, Arizona. 

 

“The cloud-based viewer gives us instant access to images from anywhere, and the AI tools, like CAD for lesion detection and automated breast density assessment, can help us deliver fast and consistent results. It’s not just about speed, it’s about confidence. With Breast Suite, our team can make more accurate decisions without workflow disruptions, which ultimately means better care for our patients.”

 

The expanded Breast Suite platform already includes AI-powered cancer detection, automated density assessment, prioritized worklists, reporting tools, and real-time alerts. New applications being rolled out include:

 

1. ProFound Pro, a clinical AI tool designed to localize lesions and assess suspicion levels across both 2D and 3D mammograms, including in dense breast tissue, alongside automated density classification.

 

2. Safeguard Review, an optional AI workflow that flags complex cases for secondary review. In large US studies, a multistage AI-driven workflow showed a 21% increase in cancer detection overall and a 23% increase in women with dense breasts compared with standard care.

 

“At DeepHealth, we are committed to bringing the next era of AI-powered health informatics to help stage shift disease,” said Niccolo Stefani, Business Leader Population Health & Clinical AI, DeepHealth. 

 

“Through our expanded collaboration with GE HealthCare, we are bringing the power of our new Breast Suite to providers around the world to enable early cancer detection, deeper clinical insights, and more confident decisions. Together we are pushing the boundaries of what mammography can deliver, not only for breast cancer screening but for women’s health more broadly.”